Prelude Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-98,346
Closed -$670K – 1634
2026
Q2
$670K Buy
+98,346
New +$582K 0.05% 415
2024
Q3
– Sell
-186,591
Closed -$418K – 1549
2024
Q2
$418K Buy
186,591
+130,698
+234% +$380K 0.03% 622
2024
Q1
$160K Sell
55,893
-133,983
-71% -$279K 0.01% 1150
2023
Q4
$336K Sell
189,876
-50,375
-21% -$100K 0.02% 686
2023
Q3
$759K Buy
+240,251
New +$449K 0.05% 369

Other funds holding TSHA

Prelude Capital Management's TSHA Position: Q3 2026 in Review

Prelude Capital Management sold out of Taysha Gene Therapies (TSHA) in Q3 2026, closing a stake of 98,346 shares — an estimated $670K sold.

Prelude Capital Management first reported a position in TSHA in Q3 2023 and held it in 5 quarters. The position peaked at $759K in Q3 2023. 205 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

  • Prelude Capital Management reported no remaining Taysha Gene Therapies position as of Q3 2026 after selling out during the quarter.
  • Prelude Capital Management sold 98,346 Taysha Gene Therapies shares in Q3 2026, an estimated $670K.
  • Prelude Capital Management first reported a position in Taysha Gene Therapies in Q3 2023 and held it in 5 quarters.
  • Prelude Capital Management's Taysha Gene Therapies position peaked at $759K in Q3 2023.
  • 205 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on Prelude Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.